Modest, D., von Weikersthal, L. F., Decker, T., Vehling-Kaiser, U., Uhlig, J., Schenk, M., Freiberg-Richter, J., Peuser, B., Denzlinger, C., Reddemann, C. P. g., Graeven, U., Schuch, G., Schwaner, I., Stahler, A., Jung, A., Kirchner, T., Held, S., Stintzing, S., Giessen-Jung, C., Heinemann, V., & , (n.d.). pD-020Age and RAS status to select patients with metastatic colorectal cancer (mCRC) for initial sequential versus combination therapy including fluoropyrimidines (FP), irinotecan (Iri) and bevacizumab (Bev): XELAVIRI- study. Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095477202.0x000036